Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy

Vanessa Ibrahim; Catherine Isroff; Christopher D. Stephen; Jay Iyer; Marian L. Dale; Douglas A. Gunzler; Ece Bayram; Tao Xie; Alex Pantelyat; Leila Montaser-Kouhsari; Indira Garcia-Cordero; Maria Carmela Tartaglia; Anthony E. Lang; Matthew Swan; Adam L. Boxer; Lawrence I. Golbe; Anne Marie Wills

doi:10.3389/fneur.2024.1501206

Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy

Vanessa Ibrahim
, Catherine Isroff
, Christopher D. Stephen
, Jay Iyer
, Marian L. Dale
, Douglas A. Gunzler
, Ece Bayram
, Tao Xie
, Alex Pantelyat
, Leila Montaser-Kouhsari
, Indira Garcia-Cordero
, Maria Carmela Tartaglia
, Anthony E. Lang
, Matthew Swan
, Adam L. Boxer
, Lawrence I. Golbe
, Anne Marie Wills

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed. Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials. Methods: Cognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation. Results: There was a significant decline in the MoCA score over time of −1.4 (95% CI −0.84 to −1.97) points over a 48-week period (p < 0.0001). Small but significant changes (p < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time (r_rm = 0.1, p = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) (r_rm = −0.25, p < 0.0001). Conclusion: The MoCA appears to have limited sensitivity in capturing cognitive decline in PSP.

Original language	English (US)
Article number	1501206
Journal	Frontiers in Neurology
Volume	15
DOIs	https://doi.org/10.3389/fneur.2024.1501206
State	Published - 2024

Keywords

MoCA = Montreal Cognitive Assessment
PSP
cognitive outcome measure
fluency
progressive supranucelar palsy

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.3389/fneur.2024.1501206

Cite this

Ibrahim, V., Isroff, C., Stephen, C. D., Iyer, J., Dale, M. L., Gunzler, D. A., Bayram, E., Xie, T., Pantelyat, A., Montaser-Kouhsari, L., Garcia-Cordero, I., Tartaglia, M. C., Lang, A. E., Swan, M., Boxer, A. L., Golbe, L. I., & Wills, A. M. (2024). Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy. Frontiers in Neurology, 15, Article 1501206. https://doi.org/10.3389/fneur.2024.1501206

Ibrahim, V, Isroff, C, Stephen, CD, Iyer, J, Dale, ML, Gunzler, DA, Bayram, E, Xie, T, Pantelyat, A, Montaser-Kouhsari, L, Garcia-Cordero, I, Tartaglia, MC, Lang, AE, Swan, M, Boxer, AL, Golbe, LI & Wills, AM 2024, 'Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy', Frontiers in Neurology, vol. 15, 1501206. https://doi.org/10.3389/fneur.2024.1501206

@article{7bd6c915dbc64b65b6424b83e4505719,

title = "Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy",

abstract = "Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed. Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials. Methods: Cognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation. Results: There was a significant decline in the MoCA score over time of −1.4 (95\% CI −0.84 to −1.97) points over a 48-week period (p < 0.0001). Small but significant changes (p < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time (rrm = 0.1, p = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) (rrm = −0.25, p < 0.0001). Conclusion: The MoCA appears to have limited sensitivity in capturing cognitive decline in PSP.",

keywords = "MoCA = Montreal Cognitive Assessment, PSP, cognitive outcome measure, fluency, progressive supranucelar palsy",

author = "Vanessa Ibrahim and Catherine Isroff and Stephen, \{Christopher D.\} and Jay Iyer and Dale, \{Marian L.\} and Gunzler, \{Douglas A.\} and Ece Bayram and Tao Xie and Alex Pantelyat and Leila Montaser-Kouhsari and Indira Garcia-Cordero and Tartaglia, \{Maria Carmela\} and Lang, \{Anthony E.\} and Matthew Swan and Boxer, \{Adam L.\} and Golbe, \{Lawrence I.\} and Wills, \{Anne Marie\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2024 Ibrahim, Isroff, Stephen, Iyer, Dale, Gunzler, Bayram, Xie, Pantelyat, Montaser-Kouhsari, Garcia-Cordero, Tartaglia, Lang, Swan, Boxer, Golbe and Wills.",

year = "2024",

doi = "10.3389/fneur.2024.1501206",

language = "English (US)",

volume = "15",

journal = "Frontiers in Neurology",

issn = "1664-2295",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy

AU - Ibrahim, Vanessa

AU - Isroff, Catherine

AU - Stephen, Christopher D.

AU - Iyer, Jay

AU - Dale, Marian L.

AU - Gunzler, Douglas A.

AU - Bayram, Ece

AU - Xie, Tao

AU - Pantelyat, Alex

AU - Montaser-Kouhsari, Leila

AU - Garcia-Cordero, Indira

AU - Tartaglia, Maria Carmela

AU - Lang, Anthony E.

AU - Swan, Matthew

AU - Boxer, Adam L.

AU - Golbe, Lawrence I.

AU - Wills, Anne Marie

PY - 2024

Y1 - 2024

N2 - Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed. Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials. Methods: Cognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation. Results: There was a significant decline in the MoCA score over time of −1.4 (95% CI −0.84 to −1.97) points over a 48-week period (p < 0.0001). Small but significant changes (p < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time (rrm = 0.1, p = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) (rrm = −0.25, p < 0.0001). Conclusion: The MoCA appears to have limited sensitivity in capturing cognitive decline in PSP.

AB - Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed. Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials. Methods: Cognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation. Results: There was a significant decline in the MoCA score over time of −1.4 (95% CI −0.84 to −1.97) points over a 48-week period (p < 0.0001). Small but significant changes (p < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time (rrm = 0.1, p = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) (rrm = −0.25, p < 0.0001). Conclusion: The MoCA appears to have limited sensitivity in capturing cognitive decline in PSP.

KW - MoCA = Montreal Cognitive Assessment

KW - PSP

KW - cognitive outcome measure

KW - fluency

KW - progressive supranucelar palsy

UR - https://www.scopus.com/pages/publications/85214380679

UR - https://www.scopus.com/pages/publications/85214380679#tab=citedBy

U2 - 10.3389/fneur.2024.1501206

DO - 10.3389/fneur.2024.1501206

M3 - Article

C2 - 39777317

AN - SCOPUS:85214380679

SN - 1664-2295

VL - 15

JO - Frontiers in Neurology

JF - Frontiers in Neurology

M1 - 1501206

ER -

Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this